As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

Merck (NYSE:MRK) has received FDA approval for Enflonsia, a prophylactic antibody therapy designed to protect infants from respiratory syncytial virus (RSV) in a market dominated by Beyfortus, a rival ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

A wall showing a Merck & Co. logo in Kenilworth, New Jersey This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...

The FDA began a safety review of RSV monoclonal antibody treatments for infants despite the products' safety records.

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

Please provide your email address to receive an email when new articles are posted on . Clesrovimab is a monoclonal antibody that protects against RSV subtypes A and B. The FDA set a PDUFA date for ...

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to ...

FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.

The Food and Drug Administration on Monday approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a ...

The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck ...